Abstract：Objective To investigate the clinical manifestations, diagnosis, and treatment of peripheral primitiveneuroectodermal tumor (pPNET) in children and the survival of patients treated with the CCG7942/POG9354 protocol.Methods A retrospective analysis was performed on the clinical data of 10 patients with pPNET admitted from October 2008 to October 2013. Of the 10 patients, 3 had metastasis, while others had no metastasis. The 7 patients withoutmetastasis were treated with the Children's Cancer Study Group 7942 (CCG7942) protocol, and the other 3 patients with metastasis with the Pediatric Oncology Group 9354 (POG9354) protocol. The therapeutic response and chemotherapy related toxicities were evaluated by WHO criteria and Common Terminology Criteria for Adverse Events (version 4.0).Results In the 7 patients treated with the CCG7942 protocol, 4 achieved a complete remission (CR), 1 had stabledisease, 2 developed progressive disease (PD), and 2 had recurrence. In the 3 patients treated with the POG9354 protocol, 1achieved a CR, 2 developed PD, 2 had recurrence, and 2 died. For the 7 patients without metastasis, the survival timewas 5-60 months, and the event-free survival rate was 71%. For the 3 patients with metastasis, the survival time was 13-25 months, and the event-free survival rate was 33%. All patients developed grade 4 bone marrow suppression, and othergrade 1-2 toxicities, including gastrointestinal reactions, liver function impairment, and renal function impairment, werealso seen. Conclusions CCG7942 protocol is effective and safe for children with non-metastatic pPNET. However,POG9354 protocol has unsatisfactory efficacy in children with metastatic pPNET, so further studies are needed toimprove the therapy for this disease.
QU Kui-Yao,TANG Suo-Qin,FENG Chen et al. Clinical efficacy of CCG7942/POG9354 protocol in treatment of peripheral primitive neuroectodermal tumor in children[J]. CJCP, 2014, 16(11): 1109-1113.
Fraumeni JF, Glass AG. Rarity of Ewing's sarcoma among US. Negro children[J]. Lancet, 1970, 1(7462):366-367.
[2]
Carvajal R, Meyers P. Ewing's sarcoma and primitive neuroectodermal family of tumors[J]. Hematol Oncol Clin North Am, 2005, 19(3):501-525.
[3]
Schulman H, Newman-Heinman N, Kurtzbart E, et al. Thoracoabdominal peripheral primitive neuroectoderma1 tumors in children:radiological features[J]. Eur Radiol, 2000, 10(10):1649-1652.
[4]
Kiatsoontorn K, Takami T, Ichinose T, et al. Primary epidural peripheral primitive neuroectodermal tumor of the thoracic spine[J]. Neurol Med Chir(Tokyo), 2009, 49(11):542-545.
[5]
Ohgaki K, Horiuchi K, Mizutani S, et al. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney that responded to low-dose chemotherapy with ifosfamide, etoposide, and doxorubicin[J]. Int J Clin Oncol, 2010, 15(2):210-214.
[6]
Womer RB, West DC, Krailo MD, et al. A randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing's sarcoma:a report from the Children's Oncology Group[J]. J Clin Oncol, 2012, 30(33):4148-4154.
[7]
Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone[J]. N Engl J Med, 2003, 348(8):694-701.
[8]
Luksch R, Tienghi A, Hall KS, et al. Primary metastatic Ewing's family tumors:results of the Italian Sarcoma Group and Scandinavian Sarcoma Group ISG/SSG IV Study including myeloablative chemotherapy and total-lung irradiation[J]. Ann Oncol, 2012, 23(11):2970-2976.
[9]
Drabko K, Raciborska A, Bilska K, et al. Consolidation of firstline therapy with busulphan and melphalan, and autologous stem cell rescue in children with Ewing's sarcoma[J]. Bone Marrow Transplant, 2012, 47(12):1530-1534.
[10]
Atra A, Whelan JS, Calvagna V, et al. High-dose busulfan/melphalan with autologous stem cell rescue in Ewing's sarcoma[J]. Bone Marrow Transplant, 1997, 20(10):843-846.
[11]
Meyers PA, Krailo MD, Ladanyi M, et al. High-dose melphalan, etoposide, total-body irradiation and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis[J]. J Clin Oncol, 2001, 19(11):2812-2820.
